New recommendations for the diagnosis and the treatment of Helicobacter pylori infection;Nouvelles recommandations pour le diagnostic et le traitement de l'infection à Helicobacter pylori

Presse Medicale

Volumn 42, Issue 3, 2013, Pages 309-317

  de Korwin, Jean Dominique ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BISMUTH; CLARITHROMYCIN; NONSTEROID ANTIINFLAMMATORY AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIUM DETECTION; CANCER RISK; CYANOCOBALAMIN DEFICIENCY; DYSPEPSIA; ERADICATION THERAPY; FRANCE; HELICOBACTER INFECTION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IRON DEFICIENCY ANEMIA; PEPTIC ULCER; SERODIAGNOSIS; SHORT SURVEY; STOMACH BIOPSY; STOMACH CANCER; UREA BREATH TEST;

HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84875275988     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2012.07.014     Document Type: Short Survey

References (30)

1. Malfertheiner P., Mégraud F., O'Morain C.A., Atherton J., Axon A.T.R., Bazzoli F., et al. Management of Helicobacter pylori infection - the Maastricht IV/Florence consensus report. Gut 2012, 61:646-664.
2. Chey W.D., Wong B.C.Y. American College of Gastroenterology guideline on management of Helicobacter pylori infection. Am J Gastroenterol 2007, 102:1-18.
3. Afssaps ; recommandations de bonnes pratiques : les antisécrétoires gastriques chez l'adulte ; novembre 2007. http://agmed.sante.gouv.fr/pdf/5/rbp/antisecretoire-gastrique-reco.pdf.
4. de Korwin J.D. Helicobacter pylori. Gastroenterol Clin Biol 2007, 31:1110-1117.
5. Sung J.J.Y., Kuipers E.J., El-Serag H.B. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther 2009, 29:938-946.
6. Laine L., Curtis S.P., Cryer B., Kaur A., Cannon C.P. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34,701 arthritis patients. Aliment Pharmacol Ther 2010, 32:1240-1248.
7. Ruskone-Fourmestraux A., Fischbach W., Aleman B.M., Boot H., Du M.Q., Mégraud F., et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011, 60:747-758.
8. Ford A.C., Moayyedi P., Jarbol D.E., Logan R.F., Delaney B.C. Meta-analysis: Helicobacter pylori "test and treat" compared with empirical acid suppression for managing dyspepsia. Aliment Pharmacol Ther 2008, 28:534-544.
9. Harvey R.F., Lane J.A., Nair P., Egger M., Harvey I., Donovan J., et al. Clinical trial: prolonged beneficial effect of Helicobacter pylori eradication on dyspepsia consultations - the Bristol Helicobacter Project. Aliment Pharmacol Ther 2010, 32:394-400.
10. Yaghoobi M., Farrokhyar F., Yuan Y., Hunt R.H. Is there an increased risk of GERD after Helicobacter pylori eradication? A meta-analysis. Am J Gastroenterol 2010, 105:1007-1013.
11. Fox J.G., Kuipers E.J. Long-term proton pump inhibitor administration, H. pylori and gastric cancer: lessons from the gerbil. Gut 2011, 60:567-568.
12. Polk D.B., Peek R.M. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer 2010, 10:403-414.
13. Wang J., Xu L., Shi R., Huang X., Li S.W., Zhang G. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion 2011, 83:253-260.
14. Rugge M., de Boni M., Pennelli G., de Bona M., Giacomelli L., Fassan M., et al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther 2010, 31:1104-1111.
15. Fuccio L., Zagari R.M., Eusebi L.H., Laterza L., Cennamo V., Ceroni L., et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?. Ann Intern Med 2009, 151:121-128.
16. Yanaoka K., Oka M., Ohata H., Yoshimura N., Deguchi H., Mukoubayashi C., et al. Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels. Int J Cancer 2009, 125:2697-2703.
17. Rokkas T., Sechopoulos P., Pistiolas D., Margantinis G., Koukoulis G. Helicobacter pylori infection and gastric histology in first-degree relatives of gastric cancer patients: a meta-analysis. Eur J Gastroenterol Hepatol 2010, 22:1128-1133.
18. de Korwin J.D. Does Helicobacter pylori infection play a role in extragastric diseases?. Presse Med 2008, 37(3 Pt 2):525-534.
19. Qu X.H., Huang X.L., Xiong P., Zhu C.Y., Huang Y.L., Lu L.G., et al. Does Helicobacter pylori infection play a role in iron deficiency anemia? A meta-analysis. World J Gastroenterol 2010, 16:886-896.
20. Stasi R., Sarpatwari A., Segal J.B., Osborn J., Evangelista M.L., Cooper N., et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood 2009, 113:1231-1240.
21. Mégraud F., Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007, 20:280-322.
22. Cambau E., Allerheiligen V., Coulon C., Corbel C., Lascols C., Deforges L., et al. Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori. J Clin Microbiol 2009, 47:3600-3607.
23. Fauchère J.L., Charlie-Bret N., Courillon-Mallet A., de Korwin J.D., Raymond J., Burucoa C., et al. évaluation comparative de 29 trousses commercialisées pour le diagnostic sérologique de l'infection par Helicobacter pylori : étude multicentrique du Groupe d'étude Français des Helicobacters. Feuill Biol 2011, LII:298-307.
24. Raymond J., Lamarque D., Kalach N., Chaussade S., Burucoa C. High level of antimicrobial resistance in French Helicobacter pylori isolates. Helicobacter 2010, 15:21-27.
25. Graham D.Y., Rimbara E. Understanding and appreciating sequential therapy for Helicobacter pylori eradication. J Clin Gastroenterol 2011, 45:309-313.
26. Gisbert J.P., Calvet X., O'Connor A., Mégraud F., O'Morain C.A. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010, 44:313-325.
27. Wu D.C., Hsu P.I., Wu J.Y., Opekun A.R., Kuo C.H., Wu I.C., et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of H. pylori infection. Clin Gastroenterol Hepatol 2010, 8:36-41.
28. Malfertheiner P., Bazzoli F., Delchier J.C., Celinski K., Giguère M., Rivière M., et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011, 377:905-913.
29. Gisbert J.P., Bermejo F., Castro-Fernandez M., Pérez-Aisa A., Fernandez-Bermejo M., Tomas A., et al. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am J Gastroenterol 2008, 103:71-76.
30. Miehlke S., Hansky K., Schneider-Brachert W., Kirsch C., Morgner A., Madisch A., et al. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Aliment Pharmacol Ther 2006, 24:395-403.